ATLANTA, July 10, 2018 /PRNewswire/ -- Rimidi, Inc., a digital health company that provides software and clinical analytics for chronic disease management, today announced it has raised $6.575 million in Series A-1 financing, which includes a strategic investment by Eli Lilly and Company, an investment from Turner Investments, and participation from existing investors Cox Enterprises, Village Capital, The Jump Fund, and JAMB Global. Both Lilly and Turner will take board seats.
The Series A-1 financing will fuel Rimidi's growth and accelerate its market penetration. Formerly known as Rimidi Diabetes, Inc., the Company is rebranding to Rimidi, Inc. to reflect the expansion of its platform and mission to broadly address cardiometabolic disease.
"We are excited to close this successful round, and focus on the road ahead," stated Rimidi CEO Josh Claman. "Helping healthcare providers transition to more proactive and data-driven care delivery models is proving again and again to improve health outcomes and reduce the avoidable complications of these diseases. This round will allow us to push more aggressively into the market and accelerate our expansion into other cardio-metabolic comorbidities."
"We believe Rimidi is particularly well-positioned to address the complex issue of personalizing treatment decisions across large populations of people with diabetes," said Marie Schiller, vice president, Connected Care and site head, Cambridge Innovation Center."Rimidi has become a key partner in our connected diabetes ecosystem strategy, and we look forward to supporting their journey as they broaden their impact both in the US and internationally."
Rimidi's platform helps clinicians personalize care for individuals by leveraging both patient generated data, clinical information, and the latest practice guidelines. The platform enables clinicians to identify individuals who may benefit from specific therapeutic approaches. The platform integrates with leading electronic medical records systems, providing a seamless workflow experience for clinicians at the point of care.
Advertisement
The Series A-1 financing will fuel Rimidi's growth and accelerate its market penetration. Formerly known as Rimidi Diabetes, Inc., the Company is rebranding to Rimidi, Inc. to reflect the expansion of its platform and mission to broadly address cardiometabolic disease.
Advertisement
"We are excited to close this successful round, and focus on the road ahead," stated Rimidi CEO Josh Claman. "Helping healthcare providers transition to more proactive and data-driven care delivery models is proving again and again to improve health outcomes and reduce the avoidable complications of these diseases. This round will allow us to push more aggressively into the market and accelerate our expansion into other cardio-metabolic comorbidities."
"We believe Rimidi is particularly well-positioned to address the complex issue of personalizing treatment decisions across large populations of people with diabetes," said Marie Schiller, vice president, Connected Care and site head, Cambridge Innovation Center."Rimidi has become a key partner in our connected diabetes ecosystem strategy, and we look forward to supporting their journey as they broaden their impact both in the US and internationally."
Rimidi's platform helps clinicians personalize care for individuals by leveraging both patient generated data, clinical information, and the latest practice guidelines. The platform enables clinicians to identify individuals who may benefit from specific therapeutic approaches. The platform integrates with leading electronic medical records systems, providing a seamless workflow experience for clinicians at the point of care.
View original content:http://www.prnewswire.com/news-releases/rimidi-closes-6-575-million-series-a-with-strategic-investment-from-eli-lilly-300678588.html
SOURCE Rimidi
